相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Eleonora Marostica et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
Adrian Wiestner
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader et al.
BLOOD (2012)
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
Adrian Wiestner
BLOOD (2012)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
B-cell receptor signaling in chronic lymphocytic leukemia
Freda K. Stevenson et al.
BLOOD (2011)
Update on Therapy of Chronic Lymphocytic Leukemia
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products
Soonmo Peter Kang et al.
CLINICAL CANCER RESEARCH (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Primary B Cell Immunodeficiencies: Comparisons and Contrasts
Mary Ellen Conley et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Cutting edge: Constitutive B cell receptor signaling is critical for basal growth of B lymphoma
Murali Gururajan et al.
JOURNAL OF IMMUNOLOGY (2006)
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
A Rinaldi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
JC Byrd et al.
BLOOD (2005)
Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by toll-like receptor 4
CA Jefferies et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
